Livdelzi, which Gilead inherited through its acquisition of CymaBay, will now compete with medicines for primary biliary cholangitis that are currently marketed by Ipsen and Alfasigma.
Read more about this post on BioPharmaDive
Trending
- Natural Cervical Ripening to Prevent Pharmacological Induction of Labor – a Pilot Study.
- Combined rTMS and tSCS for Upper Limb Recovery in Cervical SCI
- Comparison of the Italian and U.S. Forensic Models for Dual-diagnosis Offenders: a 3-year Longitudinal Study
- Celebrating the Class of 2026: Spring Commencement at the College of Medicine and Life Sciences
- Enhancing Strategic Academic Ties Between Indonesia and Turkiye
- Regeneron Partners with Parabilis to Propel Innovative Antibody-Helicon Conjugates in Diverse Therapies
- Mastering Job Offer Negotiation in Biotech
- Shareholder Support for Incentive Plan Boosts Ultragenyx Potential
